The effect of positively framing side-effect risk in two different formats on side-effect expectations, informed consent and credibility: A randomised trial of 16- to 75-year-olds in England by Webster, R. & Rubin, G.J.
This is a repository copy of The effect of positively framing side-effect risk in two different 
formats on side-effect expectations, informed consent and credibility: A randomised trial of 
16- to 75-year-olds in England.




Webster, R. orcid.org/0000-0002-5136-1098 and Rubin, G.J. (2020) The effect of positively
framing side-effect risk in two different formats on side-effect expectations, informed 
consent and credibility: A randomised trial of 16- to 75-year-olds in England. Drug Safety. 
ISSN 0114-5916 
https://doi.org/10.1007/s40264-020-00959-8
This is a post-peer-review, pre-copyedit version of an article published in Drug Safety. The 





Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless 
indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by 
national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of 
the full text version. This is indicated by the licence information on the White Rose Research Online record 
for the item. 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
 
The effect of positively framing side-effect risk in two different formats on side-effect 
expectations, informed consent and credibility: A randomised trial of 16-75 year olds in 
England. 
 
Running head: Impact of positive framing on side-effect expectations, credibility and 
informed consent 
 
Webster, R.K (0000-0002-5136-1098)1* and Rubin, G.J (0000-0002-4440-0570)2,3 
 
1 University of Sheffield, Department of Psychology, Cathedral Court, 1 Vicar Lane, 
Sheffield, United Kingdom 
2 King's College London, Institute of Psychiatry, Psychology and Neuroscience, Department 
of Psychological Medicine, Weston Education Centre, Denmark Hill,  London, United 
Kingdom 
3 National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in 
Emergency Preparedness and Response at King’s College London  




We would like to thank the study participants for their time in completing this survey, and 
Penny and team from Ipsos MORI for carrying out the data collection. Ipsos MORI was 
responsible for the fieldwork and data collection only and not responsible for the 




Background: Reframing side-effect information in patient information leaflets (PILs) in terms 
of those who remain side-effect free may reduce negative expectations and side-effects, 
although there are concerns this may impact informed consent. This study compared two 
versions of positively framed PILs to current practice to see which reduces side-effect 
expectations whilst maintaining informed consent and credibility. 
Methods: We commissioned Ipsos MORI to conduct an online survey of 16-75s in England. 
1067 people completed the study and were randomised to receive a PIL for a hypothetical 
new antibiotic that either communicated side-effects following current practice (n=356), used 
positive framing with natural frequencies (n=356), or positive framing with percentages 
(n=355). After reading the leaflet participants completed measures of their side-effect 
expectations, absolute risk perceptions, and satisfaction and credibility of the leaflet. 
Results: Both positively framed PILs resulted in significantly lower side-effect expectations 
compared to the current PIL for all side-effects (p’s<.001), apart from seizure. Pairwise 
comparisons showed no difference in side-effect expectations between the two positively 
framed PILs (p’s>.626). The positively framed PIL using natural frequencies produced more 
accurate risk perceptions than the same leaflet using percentages; but performed equally to 
the current PIL. There was no difference between the leaflets in terms of satisfaction with or 
credibility of the PILs 
Conclusion: Positively framed PILs using natural frequencies significantly reduced side-
effect expectations and provided the most accurate risk perceptions without impacting 
satisfaction or credibility. Replication is needed with patients prescribed new medication and 
those with lower educational status. 
Key points 
 Positively framing patient information leaflets (PILs) using natural frequencies 
reduces side-effect expectations with no seeming repercussions on satisfaction, 
credibility of the PIL or informed consent. 
 Policy makers should consider how side-effect risk is framed in PILs, but first 
replication is needed in a clinical sample and those with lower educational status 
 Consideration also needs to be given to the verbal risk descriptors used in positively 
framed PILs  
1 Introduction 
It is widely acknowledged that medications may generate adverse effects. Around 6.5% of 
hospital admissions are related to these adverse effects [1]. As such adverse effects (or side-
effects, as we will refer to them following the terminology used in patient information 
leaflets) can be a great cause for concern to patients, reducing their quality of life and well-
being, as well as influencing their adherence and therefore the therapeutic benefit of the 
medication [2-4]. As a result, side-effects can cost health services (such as the National 
Health Service in the United Kingdom) billions in additional healthcare costs due to GP and 
A&E visits, additional prescriptions to combat side-effects and unused medication [5]. 
Not all side-effects are related to the pharmacological action of medications [6, 7]. Many 
consist of nonspecific symptoms which are attributed to the medication [8]. These 
nonspecific side-effects can arise through a psychological phenomenon known as the nocebo 
effect in which these noxious symptoms are largely generated through negative expectations 
[9], e.g. after reading accompanying patient information leaflets (PILs) containing a detailed 
and lengthy list of possible side-effects. 
If we can reduce the occurrence of nocebo effects we could therefore reduce the experience 
of side-effects. There is rife debate in the literature about the effectiveness (and ethics) of 
withholding side-effect information to reduce expectations and therefore nocebo induced 
side-effects [10]. However, although this might reduce side-effects, it does not follow the 
ruling of the UK Supreme Court that doctors should not ‘cherry pick’ the risk information 
given to patients [11]. One potential resolution is the use of positive framing [12, 13].  
The framing effect reflects a type of cognitive bias, where people respond differently to a 
described probability depending on how it is portrayed; e.g. as a loss (negative) or as a gain 
(positive) [14]; and has been shown to influence therapy preference [15], and health-related 
behaviours [16]. According to current guidelines, medication side-effect information is 
communicated in PILs with side-effects listed in the order of their commonality, explaining 
the number of people who will be affected (e.g. ‘Common, may affect up to 1 in 10 people ’) 
[17]. However,   this leads to gross overestimation of side-effect risk in the general public as 
people interpret ‘common’ as meaning more than chance i.e. greater than 5 in 10 which is in 
conflict with the numerical descriptor, as such it has been found that combined descriptors 
can lead to a relative overestimation of risk of up to 800%  [18-20]. Reframing side-effects 
positively, to communicate the number of people who will remain side-effect free, is an 
example of libertarian paternalism [21], in which ‘nudge’ techniques can guide people’s 
choices so that outcomes improve, without withholding any information that would therefore 
impact informed consent or patient autonomy. Positive framing could therefore not only 
reduce non-adherence through reducing the nocebo effect but also reduce intentional non-
adherence whereby people are put off by long lists of side-effects and decide not to take the 
medication [22].  
Positively framing side-effect risk in PILs significantly reduces side-effect occurrence in 
healthy volunteers taking a sham medicine compared to current practice [23] and without 
altering their perceptions of the trustworthiness of the information. However, positively 
framed side-effect risk information can be presented in various ways [13]. These include 
verbal descriptors, natural frequencies and percentages, which may influence side-effect risk 
perception to varying degrees [24]. In addition there is concern that positive framing may 
reduce patients’ side-effect expectations and absolute risk perceptions to the extent that 
informed consent is no longer upheld [13]. 
There is a need to identify the optimal method of presenting positively framed side-effect 
information, to test which best helps readers to form accurate side-effect expectations and 
estimates of absolute risk while also maintaining the reader’s trust and informed consent. 
1.1 Research objectives 
The aim of this study was to identify the optimal method of presenting positively framed 
side-effect information by exploring the effect of information about side effects which 
consists of combined verbal and natural frequency information, or verbal and percentage 
information, versus current practice. Outcomes consisted of participants’: 
1. side-effect expectations 
2. perceived absolute risk of side-effects 
3. satisfaction with the PIL information  
4. perceived PIL credibility. 
2 Method 
2.1 Design 
The market research company Ipsos MORI were commissioned to conduct an online survey 
of 16 - 75 year olds living in England. Data collection commenced on the 28th October and 
was completed on the 7th November 2019. This study was approved by the Research Ethics 
Committee at King’s College London (reference MRA-19/20-14325). 
The survey incorporated a randomised controlled trial design with participants randomised to 
read one of three PILs and answer questions about them. 
2.2 Participants 
Participants were recruited from Ipsos MORI’s panel of people who had signed up to take 
part in internet surveys (approximately n = 160,000). Due to concerns that older adults on 
internet survey panels are not representative of the general population, we excluded those 
aged over 75 [25, 26].  
2.3 Sample size 
To ensure a demographically representative sample, Ipsos MORI used quotas based on 
participant age and gender (interlocked), location, and working status according to data from 
the Publishers Audience Measurement Company Ltd [27]. A sample size target of 1067 
participants was set to provide a sample error of plus or minus 3% at the total sample level. 
2.4 Procedure 
Those who met the inclusion criteria on the survey panel were emailed a link to the survey. 
After providing informed consent, participants completed baseline questions and then were 
allocated to read one of three different PILs for a hypothetical new antibiotic, Ormicillin. 
This was decided by an algorithm in the survey software which allocated participants to the  
condition which had the lowest number of completed responses at that time. After reading 
their assigned leaflet, participants were asked about their side-effect expectations, absolute 
side-effect risk perceptions, and satisfaction and credibility of information in the PIL. After 
completing the survey participants received 100 ‘credits’ (equivalent to £1). 
To ensure participant attention in the survey, we had a range of checks in place. Firstly, based 
on the average reading speed and the ability of people to effectively speed read [28] we used 
a time monitor once participants had reached the PIL so that those who clicked forward to the 
next question in less than one minute were automatically screened out of the survey. 
Secondly, we had three attention check questions after the leaflet (e.g. taking this medication 
should not affect your ability to drive or operate machinery – true/false), and participants who 
got any of these questions wrong were also screened out.  
2.5 Materials  
2.5.1 Demographic characteristics 
Participants were asked demographic questions concerning their age, gender, ethnicity, 
highest level of education, employment status and health. 
2.5.2 Patient information leaflets 
The three leaflets contained identical information (apart from the side-effect section), and 
were based on a current leaflet in use for penicillin [29]. The control leaflet used the current 
recommended practice for communicating side-effect information, (e.g. Common, up to 1 in 
10 people are affected), the positively framed natural frequency leaflet used positive side-
effect framing with natural frequency descriptors (e.g. Uncommon, 9 in 10 people are not 
affected), and the positively framed percentage leaflet used positive framing with percentage 
descriptors (Uncommon, 90% of people are not affected). See Table 1 for differences in side-
effect section between the three PILs, and the electronic supplementary material for a full 
copy of PILs. 
  
Table 1. Side-effect section in each of the three PILs 
Current PIL  +ve frame natural frequencies  +ve frame percentages  
Very common (more than 1 in 10 people are affected) 
 stomach pain 
 diarrhoea 
 
Common (up to 1 in 10 people are affected) 
 nausea 
 vomiting 
 black "hairy" tongue 
 chills or fever  
 severe skin rash, itching or peeling  
 
Uncommon (up to 1 in 100 people are affected) 
 difficulty breathing 
 dizziness 
 swelling of the face or throat 
 pain and swelling of the joints (arthritis) 
 
Rare (up to 1 in 1000 people are affected) 
 various forms of anaemia (reduction in red blood 
cells) causing pale skin, or weakness 
 other blood disorders causing excessive bleeding 
(including blood in your urine or stools), bruising, 
sore throat, or general illness  
 
Very rare (up to 1 in 10,000 people are affected) 
 kidney problems 
 seizures (fits). 
Uncommon (8 in 10 people are not affected) 
 stomach pain 
 diarrhoea 
 
Very uncommon (9 in 10 people are not affected) 
 nausea 
 vomiting 
 black "hairy" tongue 
 chills or fever  
 severe skin rash, itching or peeling   
 
Rare (99 in 100 people are not affected) 
 difficulty breathing 
 dizziness 
 swelling of the face or throat 
 pain and swelling of the joints (arthritis) 
 
Very rare (999 in 1000 people are not affected) 
 various forms of anaemia (reduction in red 
blood cells) causing pale skin, or weakness 
 other blood disorders causing excessive 
bleeding (including blood in your urine or 
stools), bruising, sore throat, or general illness  
 
Extremely rare (9999 in 10,000 people are not  
affected) 
 kidney problems 
 seizures (fits). 
Uncommon (80% of people are not affected) 
 stomach pain 
 diarrhoea 
 
Very uncommon (90% of people are not affected) 
 nausea 
 vomiting 
 black "hairy" tongue 
 chills or fever  
 severe skin rash, itching or peeling  
 
Rare (99% of people are not affected) 
 difficulty breathing 
 dizziness 
 swelling of the face or throat 
 pain and swelling of the joints (arthritis) 
 
Very rare (99.9% of people are not affected) 
 various forms of anaemia (reduction in red 
blood cells) causing pale skin, or weakness 
 other blood disorders causing excessive 
bleeding (including blood in your urine or 
stools), bruising, sore throat, or general illness  
 
Extremely rare (99.99% of people are not 
affected) 
 kidney problems 
 seizures (fits). 
Note: As ‘more than 1 in 10’ does not lend itself to positive framing, the positively framed PILs gave an exact probability, +ve positive
 
2.5.3 Side-effect expectations 
One side-effect from each of the risk descriptor groups was selected and participants were 
asked how likely they would be to experience that side-effect if they took Ormicillin from a 
scale of 1 (very unlikely) to 5 (very likely). These side-effects were diarrhoea, nausea, 
dizziness, anaemia and seizure. In addition, they were asked their expectations of 
experiencing ANY side-effect. 
2.5.4 Absolute side-effect risk perceptions 
To provide an indicator of patients’ ability to provide informed consent for medication, it has 
been suggested to measure absolute risk perceptions [13]. This provides evidence of patients’ 
understanding of a certain event happening, in this case side-effects. As such for the same 
side-effects asked about with regards to their personal side-effect expectations (diarrhoea, 
nausea, dizziness, anaemia, seizure and ANY side-effect) participants were asked to estimate 
how many out of 10,000 people who take Ormicillin would develop these side-effects.  
2.5.5 Satisfaction 
Seven statements about the clarity of the information, the type of information provided, and 
overall satisfaction with the PIL were presented and rated from 1 (strongly disagree) to 5 
(strongly agree). 
2.5.6 Credibility 
Using the  Myers credibility index [30], participants rated the PIL from 1 to 5 on five 
continuums: trust, accuracy, fairness, disclosure, and bias. 
2.6 Analysis 
Due to non-normal distribution, Kruskal-Wallis tests were carried out to assess differences in 
the mean ranks for side-effect expectations, and satisfaction and credibility ratings of the PIL 
between the three conditions, and Dunn’s test was used to carry out post-hoc pairwise 
comparisons for significant results, adjusting for multiple testing using the Bonferroni 
correction. Each side-effect and item in the satisfaction and credibility ratings were analysed 
separately. 
For absolute side-effect risk perception, responses were collapsed into correct vs incorrect 
estimates based on the corresponding statistical risk descriptors (e.g. 1 in 10, 1 in 100 etc) to 
see which PIL produced the most correct estimates and differences in distributions were 
analysed using chi-square. Post-hoc pairwise comparisons were carried out for significant 
results using chi-square, adjusting for multiple testing using the Bonferroni correction.  
For all analyses, answers of ‘prefer not to say’ were excluded. See the electronic 
supplementary material for a copy of the full questionnaire and topline results.  
3 Results 
3.1 Participant characteristics 
A total of 1067 participants completed the study and were included in the final sample (see 
Fig. 1 for participant flow). Demographic characteristics of the sample are given in Table 2. 














 Fig. 1 Participant flow through the study 
Note: PIL patient information leaflet. +ve positive 
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Table 2. Demographic characteristics of the sample 
Characteristics Current PIL 
(n=356) 






Gender     
Male 172 (48.3%) 179 (50.3%) 170 (47.9%) 521 (48.8%) 
Female 184 (51.7%) 177 (49.7%) 185 (52.1%) 546 (51.2%) 
Age     
16-24 50 (14.0%) 50 (14.0%) 52 (14.6%) 152 (14.2%) 
25-34 67 (18.8%) 66 (18.5%) 66 (18.6%) 199 (18.7%) 
35-44 61 (17.1%) 62 (17.4%) 61 (17.2%) 184 (17.2%) 
45-54 67 (18.8%) 66 (18.5%) 67 (18.9%) 200 (18.7%) 
55-64 58 (16.3%) 59 (16.6%) 56 (15.8%) 173 (16.2%) 
65-75 53 (14.9%) 53 (14.9%) 53 (14.9%) 159 (14.9%) 
Ethnicity     
White 329 (93.5%) 314 (89.2%) 326 (93.4%) 969 (92.0%) 
Other 23 (6.5%) 38 (10.8%) 23 (6.6%) 84 (8.0%) 
Employment     
Working 222 (62.4%) 216 (60.7%) 221 (62.3%) 659 (61.8%) 
Not working 134 (37.6%) 140 (39.3%) 134 (37.7%) 408 (38.2%) 
Education     
No qualifications 9 (2.5%) 7 (2.0%) 15 (4.2%) 31 (2.9%) 
GCSE equivalent 84 (23.6%) 81 (22.8%) 62 (17.5%) 227 (21.3%) 
AS/A level equivalent 96 (27.0%) 76 (21.3%) 81 (22.8%) 253 (23.7%) 
Higher education 167 (46.9%) 192 (53.9%) 197 (55.5%) 556 (52.1%) 
Longstanding illness/disability     
Myself 89 (25.3%) 70 (19.8%) 85 (24.1%) 244 (23.1%) 
Someone in the household 37 (10.5%) 40 (11.3%) 39 (11.1%) 116 (11.0%) 
No 226 (64.2%) 244 (68.9%) 228 (64.8%) 698 (66.0%) 
Note: Data are n(%). PIL patient information leaflet. +ve positive 
 
3.2 Side-effect expectations 
The distribution of side-effect expectations for each of the side-effects asked about are shown 
in Table 3.. Both positively framed PILs resulted in a higher proportion of ‘unlikely/very 
unlikely’ responses for all side-effects asked about, but the difference was more pronounced 
for the more common side-effects in the PIL, i.e. diarrhoea, nausea and dizziness. Both 
positively framed PILs resulted in similar response distributions. There was no difference in 
the distribution of ‘don’t know’ responses between the three different PIL conditions, apart 
from the item ‘any side-effect’. 
Median rankings of side-effect expectations were significantly different across all PILs for 
each of the side-effects (see Table 4). Adjusting for multiple testing, pairwise comparisons 
showed that positively framed PILs using natural frequencies and percentages resulted in 
significantly lower side-effect expectations compared to the current PIL for all side-effects 
(p’s<.001), apart from seizure in which only the positively framed PIL using percentages 
resulted in significantly lower expectations (p=.008). Pairwise comparisons showed no 
significant difference in side-effect expectations  between the two positively framed PILs 
(p’s>.626). 











Diarrhoea    
Very unlikely 26 (7.3%) 76 (21.3%) 71 (20.0%) 
Unlikely 106 (29.8%) 188 (52.8%) 202 (56.9%) 
About as likely as not 92 (25.8%) 58 (16.3%) 55 (15.5%) 
Likely 82 (23.0%) 23 (6.5%) 17 (4.8%) 
Very likely 41 (11.5%) 4 (1.1%) 3 (0.8%) 
Don’t know 9 (2.5%) 7 (2.0%) 7 (2.0%) 
Nausea    
Very unlikely 33 (9.3%) 78 (21.9%) 81 (22.8%) 
Unlikely 129 (36.2%) 189 (53.1%) 206 (58.0%) 
About as likely as not 95 (26.7%) 56 (15.7%) 38 (10.7%) 
Likely 76 (21.3%) 27 (7.6%) 21 (5.9%) 
Very likely 19 (5.3%) 1 (0.3%) 3 (0.8%) 
Don’t know 4 (1.1%) 5 (1.4%) 6 (1.7%) 
Dizziness    
Very unlikely 74 (20.8%) 140 (39.3%) 136 (38.3%) 
Unlikely 160 (44.9%) 156 (43.8%) 158 (44.5%) 
About as likely as not 85 (23.9%) 40 (11.2%) 40 (11.3%) 
Likely 28 (7.9%) 11 (3.1%) 12 (3.4%) 
Very likely 3 (0.8%) 3 (0.8%) 0 (0.0%) 
Don’t know 6 (1.7%) 6 (1.7%) 9 (2.5%) 
Anaemia    
Very unlikely 162 (45.5%) 220 (61.8%) 223 (62.8%) 
Unlikely 121 (34.0%) 88 (24.7%) 93 (26.2%) 
About as likely as not 46 (12.9%) 25 (7.0%) 22 (6.2%) 
Likely 12 (3.4%) 4 (1.1%) 6 (1.7%) 
Very likely 1 (0.3%) 3 (0.8%) 0 (0.0%) 
Don’t know 14 (3.9%) 16 (4.5%) 11 (3.1%) 
Seizures    
Very unlikely 251 (70.5%) 277 (77.8%) 285 (80.3%) 
Unlikely 81 (22.8%) 56 (15.7%) 51 (14.4%) 
About as likely as not 13 (3.7%) 9 (2.5%) 10 (2.8%) 
Likely 4 (1.1%) 3 (0.8%) 3 (0.8%) 
Very likely 0 (0.0%) 4 (1.1%) 0 (0.0%) 
Don’t know 7 (2.0%) 7 (2.0%) 6 (1.7%) 
Any side-effect    
Very unlikely 38 (10.7%) 129 (36.2%) 147 (41.4%) 
Unlikely 118 (33.1%) 148 (41.6%) 144 (40.6%) 
About as likely as not 98 (27.5%) 38 (10.7%) 36 (10.1%) 
Likely 73 (20.5%) 22 (6.2%) 18 (5.1%) 
Very likely 25 (7.0%) 8 (2.2%) 7 (2.0%) 





Table 4. Difference in median side-effect likelihood rankings between the three PILs 
Side-effect likelihood Current PIL 
(n=356) 








Diarrhoea     
Median (IQR) 3 (2-4) 2 (2-2) 2 (2-2) 164.815 
p<.001 Mean rank 681.60 447.65 438.92 
Nausea     
Median (IQR) 3 (2-4) 2 (2-2) 2 (2-2) 119.180 
p<.001 Mean rank 659.57 472.95 446.14 
Dizziness     
Median (IQR) 2 (2-3) 2 (1-2) 2 (1-2) 57.098 
p<.001 Mean rank 616.09 476.56 477.32 
Anaemia     
Median (IQR) 2 (1-2) 1 (1-2) 1 (1-2) 31.627 
p<.001 Mean rank 577.98 482.95 479.59 
Seizure     
Median (IQR) 1 (1-2) 1 (1-1) 1 (1-1) 9.832 
p=.007 Mean rank 553.14 515.80 503.06 
Any     
Median (IQR) 3 (2-4) 2 (1-2) 2 (1-2) 169.356 
p<.001 Mean rank 687.56 455.67 430.39 
 
3.3 Absolute risk perceptions 
The three PILs resulted in significantly different proportions of correct and incorrect absolute 
risk perceptions, apart for the side-effect dizziness (see Table 5). Multiple comparisons 
showed that the positively framed PIL using natural frequencies overall outperformed the 
positively framed PIL using percentages; producing equally correct response for diarrhoea 
and nausea (ps>.999), but more correct responses for anaemia  and seizure (p<.001), while 
the PIL using percentages produced more correct responses for any side-effects (p=.033). 
Comparing the positively framed PIL using natural frequencies and the current PIL, multiple 
comparisons showed they performed equally, with no difference in the proportion of correct 
responses for any side-effect, anaemia, and seizure (ps>.87), with the current PIL only 
providing more correct responses for nausea (p=.042), and the positively framed PIL using 










Table 5. Difference in absolute risk perceptions between the three PILs 












Diarrhoea (1001-2000)     
Correct (%) 55 (15.4%) 224 (62.9%) 233 (65.6%) 227.107 
p<.001 Incorrect (%) 301 (84.6%) 132 (37.1%) 122 (34.4%) 
Nausea (101-1000)     
Correct (%) 275 (77.2%) 246 (69.1%) 248 (69.9%) 7.161 
p=.028 Incorrect (%) 81 (22.8%) 110 (30.9%) 107 (30.1%) 
Dizziness (11-100)     
Correct (%) 281 (78.9%) 263  (73.9%) 256 (72.1%) 4.751 
p=.093 Incorrect (%) 75 (21.1%) 93 (26.1%) 99 (27.9%) 
Anaemia (2-10)     
Correct (%) 285 (80.1%) 274 (77.0%) 192 (54.1%) 68.623 
p<.001 Incorrect (%) 71 (19.9%) 82 (23.0%) 163 (45.9%) 
Seizure (0-1)     
Correct (%) 284 (79.8%) 306 (86.0%) 192 (54.1%) 103.708 
p<.001 Incorrect (%) 72 (20.2%) 50 (14.0%) 163 (45.9%) 
Any (1001+)     
Correct (%) 77 (21.6%) 83 (23.3%) 113 (31.8%) 11.164 
p=.004 Incorrect (%) 279 (78.4%) 273 (76.7%) 242 (68.2%) 
 
3.4 Satisfaction and credibility of the PIL 
There was no significant difference between the leaflets in terms of satisfaction with or 
credibility of the PILs (see Table 6). All three leaflets scored well for both outcomes. 
 
Table 6. Difference in satisfaction and credibility ratings between the three PILs 
PIL evaluations Current PIL 
(n=356) 









Satisfaction     
Clear     
Median (IQR) 4 (4-5) 4 (4-5) 4 (4-5) 4.936 
p=.085 Mean rank 559.15 524.07 517.31 
Easy to understand     
Median (IQR) 4 (4-5) 4 (4-5) 4 (4-5) 3.603  
p=.165 Mean rank 554.77 528.31 517.44 
Words I did not understand     
Median (IQR) 2 (2-3) 2 (2-3) 2 (2-3) 3.934 
p=.140 Mean rank 553.45 532.90 511.09 
Similar to other leaflets     
Median (IQR) 5 (4-5) 4 (4-5) 4 (4-5) 3.074 
p=.215 Mean rank 552.83 528.31 517.86 
Informed choice     
Median (IQR) 4 (4-5) 4 (4-5) 4 (4-5) 0.647 
p=.724 Mean rank 532.59 524.19 540.72 
Understood risks and benefits     
Median (IQR) 4 (4-5) 4 (4-5) 4 (4-5) 0.836 
p=.659 Mean rank 542.42 534.16 523.87 
Overall satisfaction     
Median (IQR) 4 (4-5) 4 (4-5) 4 (4-5) 0.574 
Mean rank 542.12 527.75 530.61 p=.750 
Credibility     
Trusted     
Median (IQR) 4 (3-5) 4 (4-5) 4 (4-5) 4.957 
p=.084 Mean rank 506.28 549.28 546.48 
Accurate     
Median (IQR) 4 (4-5) 4 (4-5) 4 (4-5) 4.565 
p=.102 Mean rank 507.46 544.73 549.85 
Fair     
Median (IQR) 4 (4-5) 4 (4-5) 4 (4-5) 0.651 
p=.722 Mean rank 524.39 536.27 541.36 
Tells the whole story     
Median (IQR) 4 (3-5) 4 (3-5) 4 (3-5) 1.638 
p=.441 Mean rank 519.77 547.87 534.37 
Unbiased     
Median (IQR) 4 (3-5) 4 (3-5) 4 (3-5) 2.140 
p=.343 Mean rank 517.14 549.42 535.44 
 
4 Discussion 
This study looked at two different ways of presenting positively framed side-effect 
information compared current practice, to test which best helps readers to form accurate side-
effect expectations and estimates of absolute risk while also maintaining the reader’s trust 
and enabling informed consent. We found that both forms of positive framing significantly 
reduced side-effect expectations for all side-effects asked about at varying risk levels. The 
reduction in side-effect expectations was more pronounced for the more common side-effects 
such as diarrhoea and nausea, which is unsurprising as these generate the highest side-effect 
expectations under current PIL formats [19]. There was no difference in side-effect 
expectations between the two types of positively framed leaflet. 
Despite concerns that positive framing may reduce side-effect expectations to the point that 
informed consent in compromised [13], we did not find evidence for this. Absolute risk 
perceptions were recorded as an indicator of informed consent, and the results were mixed. 
Positive framing using natural frequencies produced more correct responses than the same 
PIL using percentages, replicating previous research showing natural frequencies produce 
more correct risk estimates than percentages in current PIL formats [31], however the 
positively framed PIL using natural frequencies performed on par with the current PIL. In 
addition, there was no difference between the PILs in terms of participants’ satisfaction of 
information in the PIL or ratings of credibility. As such given positive framing using natural 
frequencies significantly reduced side-effect expectations, performed equally compared to the 
current PIL in terms of participants’ ability to give informed consent and was not viewed 
negatively by participants this would seem the logical choice to use in PILs. In addition, 
future work focusing on the positive framing aspect of PILs should use natural frequencies. 
Interestingly even with the statistical risk accompanying the verbal risk descriptor, between 
14-84.6% of participants  still provided incorrect absolute risks depending on which side-
effect asked about. This supports previous studies [20] and shows that even with the 
statistical risk information many patients who read these leaflets do not understand it. 
Particularly noteworthy was that the current PIL performed poorly on communicating the risk 
for the side-effect diarrhoea (Very common, more than 1 in 10) with 84.6% of participants 
providing incorrect absolute risks (87.9% of which were underestimations). This was not 
reflected in participants’ side-effect expectations, however. Perhaps the term ‘more than’ is 
too vague and therefore participants base their estimations on the more concrete ‘1 in 10’ 
statistic.  
All leaflets also performed poorly on informing people about their risk of getting any side-
effects, with under a third of participants getting the absolute risk of ‘any side-effect’ correct, 
and this also being the item causing the greatest variation in ‘don’t responses’ between the 
three conditions. This information is not explicitly stated in PILs and our results demonstrate 
that it cannot be inferred from the information that is available.  
4.1 Implications for future research and practice 
The results suggest that guidelines for side-effect communication in patient information 
leaflets should consider using positively framed side-effect information. This will help to 
reduce side-effect expectations and therefore subsequent side-effect experience [9] which has 
implications for adherence [4]. Firstly, however, future research needs to test the impact of 
positively framing side-effect information in a clinical setting with patients taking active 
medication. Secondly, as there was not much difference between the two forms of positive 
framing, future research should also test the benefit of supplementing the information with 
visuals, such as icon arrays. Thesehave been shown to be useful when communicating 
evidence about treatment options to patients [32], and may improve the impact of positive 
framing further. Thirdly, it was striking that the majority of participants underestimated the 
absolute risk of getting ‘any’ side-effect in all three conditions. It may be that this, rather than 
details about individual side-effects, is the most important information need for patients. 
Future research should explore their perceptions around this further.  
4.2 Strength and limitations 
This is a large study, demographically representative of 16- to 75-year-olds in England. Due 
to concerns that participants over the age of 75 who take part in online surveys are not 
representative of general population they were not included in the study. However compared 
to previous similar studies [19, 18] our sample did include participants aged65-75 who are 
some of  the more heavier medication consumers [33]. While the validity of data from online 
surveys can be questioned due to concerns that participants do not read the questions properly 
or that they may be distracted with other tasks [34], this may not be an issue [35], and was 
offset by our exclusion of participants for reading the leaflet too quickly and for getting any 
one of the attention check questions wrong. Selection bias is more problematic, however, as it 
is uncertain if market research panels are psychologically representative of the general 
population’s risk perceptions towards medication side-effects. 
There is also a challenge finding wording that works for positively framing side-effect risk 
but yet is still understood by participants, as such we made two changes to the wording used 
when describing side-effect risk in order to make it more streamlined and easier to interpret 
for readers between the current and positively framed PILs. Firstly, we did not include the 
term ‘may affect…’ because of concerns that this would make the positively framed leaflets 
more cumbersome to read and interpret, e.g. “may not affect 9 in 10 people” is not that 
straightforward. Secondly, we changed the verbal descriptors for the positively framed 
leaflets to better match the statistic being presented. This was because keeping the verbal 
descriptor ‘Common’ alongside ‘9 in 10 people are not affected’ was seen as a contradiction 
to one another as people are used to interpreting the verbal descriptor as the risk of getting the 
side-effect. In addition, other options such as flipping the descriptors around and explaining 
them as the risk of not getting a side-effect, e.g. that it is ‘Very rare ’not to experience a (very 
common) side-effect such as diarrhoea also becomes difficult to interpret because of the 
double negative. As such we chose the wording to best reflect how it could work in clinical 
practice, but we acknowledge by not constraining the verbal descriptors across the control 
and positive frame condition we cannot disentangle if results seen were due to changes to the 
verbal descriptors, attribute framing, or both combined. As small changes to the wording can 
affect understanding, what is clear is that future research also needs to understand the best 
way of verbally describing positively framed side-effect risk as simply flipping the current 
format is not so straightforward. 
It is possible the response option we used to measure absolute risk perceptions could have 
affected the results. By asking participants for a number out of 10,000 this is more liable to 
overestimation compared with choosing an answer from a pre-determined set of responses 
[36]. However, this method does have benefits in this context as it is easier for participants to 
express small probabilities. In addition, by choosing a response option out of 10,000, 
participants in all three conditions had to do some conversion from the statistics they were 
presented with e.g. 1 in 10, 9 in 10 or 90%, but this may have not been as cognitively 
demanding for those presented  with natural frequencies. Future research could perhaps 
measure absolute risk perceptions with half the sample answering in natural frequencies and 
half answering in percentages to control for this. Although as we know from other studies 
that percentages are harder to understand than natural frequencies, using this as a response 
option might not be the best reflection of people’s absolute risk perceptions [31, 32] 
In addition, the questions revolved around a hypothetical scenario and as such may not be 
representative of patients who have just been prescribed a new medication. Future research 
should replicate this study in a clinical sample where participants are given side-effect 
information about an ‘actual’ prescribed medication.  Not only this, our sample were also 
highly educated with 75.8% of the total sample having A level qualifications or higher. As 
such replication is also needed with those with lower educational status as their interpretation 
of the side-effect risk presented in the PILs may be different. 
4.3 Conclusion 
Positively framed PILs using natural frequencies significantly reduced side-effect 
expectations without altering informed consent or satisfaction/credibility ratings of the PIL. 
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